Palisade Bio reported a net loss of $10.6 million ($0.05 per share) for the second quarter ended June 30, 2026, compared to a net loss of $2.8 million in the prior year period. Research and development expenses increased to $7.4 million from $1.7 million due to higher clinical operations and stock-based compensation, while general and administrative expenses rose to $4.8 million from $1.2 million. The company recognized $0.5 million in license revenue related to a milestone under its agreement with Newsoara. As of June 30, 2026, Palisade Bio held $125.2 million in cash and cash equivalents. The company announced the FDA clearance of an IND for the Phase 2 ASCENTRA-UC trial of PALI-2108 for ulcerative colitis, with enrollment expected in the second half of 2026 and primary efficacy results anticipated in the second half of 2027. Additionally, an IND submission for the Phase 2 ASCENTRA-CD trial for Crohn's disease is planned for the second half of 2026. Palisade Bio operates as a clinical-stage biopharmaceutical company developing prodrugs for inflammatory and fibrotic diseases.

On June 10, 2026, Palisade Bio, Inc. appointed Jordan Zwick to its Board of Directors and Audit Committee, expanding the Board to six members. Mr. Zwick received an initial restricted stock unit grant valued at $566,000 vesting over three years. At its annual meeting, stockholders approved increasing the number of authorized shares of common stock from 300,000,000 to 450,000,000. Stockholders also approved the Amended and Restated 2021 Equity Incentive Plan and the Amended and Restated 2021 Employee Stock Purchase Plan. The company operates in the biotechnology industry and develops therapeutic products.